Efficacy and Safety of Lianhua Qingke Tablets in Children With Mycoplasma pneumoniae Pneumonia: A Randomized, Double‐Blind, Multicenter, Placebo‐Controlled Clinical Trial
The Clinical Respiratory Journal · 2026-07 · 20 (7)
DOI: 10.1111/crj.70204 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift The Clinical Respiratory Journal, online erschienen am 25.06.2026. Verfasst von He Wang und 19 weiteren Autor:innen. Beteiligte Einrichtung: Beijing Friendship Hospital, Capital Medical University, Beijing, China. Hauptthemen laut MEDLINE: Pneumonia, Mycoplasma, Mycoplasma pneumoniae, Drugs, Chinese Herbal, Anti-Bacterial Agents. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Key Clinical Specialty Discipline Construction Program of China, Program for Cultivating High-Level Public Health Technical Talents.
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Background
Mycoplasma pneumoniae (MP) is a major cause of community‐acquired pneumonia in children, with increasing macrolide resistance complicating treatment. Traditional Chinese Medicine (TCM) provides unique benefits for pediatric respiratory infections.
Purpose
To evaluate the safety and efficacy of Lianhua Qingke (LHQK) tablets as adjunctive therapy in children with M. pneumoniae pneumonia (MPP). Study Design This prospective, multicenter, randomized, double‐blind, placebo‐controlled trial adhered to the Declaration of Helsinki and was registered in the Chinese Clinical Trial Registry (ChiCTR2300078209).
Methods
A total of 160 children aged 4–14 years with mild MPP were randomized 1:1 to receive conventional therapy plus LHQK or conventional therapy plus placebo for 7 days across 13 hospitals over 4 months. Efficacy analysis included 128 participants with centrally confirmed MP infection; safety analysis included all 160. Baseline characteristics were comparable (all p > 0.05), with 98.8% medication compliance in both groups ( p > 0.05). The primary outcome was the major symptom resolution rate by Day 7.
Results
The LHQK group showed a significantly higher major symptom resolution rate (85.9% vs. 65.6%, p < 0.05), with a numerically shorter median time to resolution (4.5 vs. 5.0 days, p = 0.072). LHQK also significantly improved cough and expectoration relief rates (all p < 0.05). No differences were found in laboratory parameters. Adverse event incidence was lower with LHQK (2.5% vs. 8.8%, p > 0.05), with no serious events reported.
Conclusion
LHQK is a safe and effective adjunctive TCM therapy for mild MPP in children, offering significant benefits in respiratory symptom alleviation and a favorable safety profile, with a trend toward shorter recovery time, providing a valuable treatment option amid rising antibiotic resistance.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Beijing Friendship Hospital, Capital Medical University, Beijing, China.
- Beijing Fengtai District Hospital of Traditional Chinese Medicine, Beijing, China.
- Seventh, Hebei Province People's Hospital, Hebei, China.
- Hebei Yiling Hospital, Hebei, China.
- Mianyang Maternal and Child Health Hospital, Sichuan, China.
- Jintang First People's Hospital, Sichuan, China.
ORCID-Profile: He Wang
Förderung
- National Key Clinical Specialty Discipline Construction Program of China
- Program for Cultivating High-Level Public Health Technical Talents
Zitieren
APA
Wang, H., Dou, H., Chen, G., Wei, Y., Li, H., Xu, S., Kang, R., Liu, S., Zhang, L., Li, N., Sun, H., Wang, C., Zhao, J., Yi, J., Song, W., Li, H., Ma, R., Shen, K., Xin, D., & Qi, W. (2026). Efficacy and Safety of Lianhua Qingke Tablets in Children With Mycoplasma pneumoniae Pneumonia: A Randomized, Double‐Blind, Multicenter, Placebo‐Controlled Clinical Trial. The Clinical Respiratory Journal, 20(7). https://doi.org/10.1111/crj.70204
Vancouver
Wang H, Dou H, Chen G, Wei Y, Li H, Xu S, et al. Efficacy and Safety of Lianhua Qingke Tablets in Children With Mycoplasma pneumoniae Pneumonia: A Randomized, Double‐Blind, Multicenter, Placebo‐Controlled Clinical Trial. The Clinical Respiratory Journal. 2026;20(7). doi:10.1111/crj.70204
BibTeX
@article{Wang2026,
author = {Wang, He and Dou, Haiwei and Chen, Guangying and Wei, Yanmin and Li, Hua and Xu, Shuqiong and Kang, Rongzhen and Liu, Shanhong and Zhang, Long and Li, Nan and Sun, Hongli and Wang, Chi and Zhao, Jie and Yi, Jirong and Song, Wentao and Li, Hongrong and Ma, Rong and Shen, Kunling and Xin, Deli and Qi, Wenjie},
title = {Efficacy and Safety of Lianhua Qingke Tablets in Children With Mycoplasma pneumoniae Pneumonia: A Randomized, Double‐Blind, Multicenter, Placebo‐Controlled Clinical Trial},
journal = {The Clinical Respiratory Journal},
year = {2026},
volume = {20},
number = {7},
doi = {10.1111/crj.70204}
}
EUVIMED